Log in
NASDAQ:XFOR

X4 Pharmaceuticals Stock Forecast, Price & News

$5.83
+0.42 (+7.76 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.41
Now: $5.83
$5.95
50-Day Range
$5.41
MA: $6.94
$8.97
52-Week Range
$5.38
Now: $5.83
$15.00
Volume81,549 shs
Average Volume84,218 shs
Market Capitalization$94.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XFOR
CUSIPN/A
CIKN/A
Phone857-529-8300
Employees64

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.37 per share

Profitability

Net Income$-52,810,000.00

Miscellaneous

Market Cap$94.95 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableNot Optionable
$5.83
+0.42 (+7.76 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

How has X4 Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XFOR shares have decreased by 32.1% and is now trading at $5.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of X4 Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for X4 Pharmaceuticals
.

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for X4 Pharmaceuticals
.

How can I listen to X4 Pharmaceuticals' earnings call?

X4 Pharmaceuticals will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its earnings results on Thursday, July, 30th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.06.
View X4 Pharmaceuticals' earnings history
.

What price target have analysts set for XFOR?

7 Wall Street analysts have issued 12 month price objectives for X4 Pharmaceuticals' stock. Their forecasts range from $15.00 to $21.00. On average, they expect X4 Pharmaceuticals' share price to reach $18.20 in the next year. This suggests a possible upside of 212.2% from the stock's current price.
View analysts' price targets for X4 Pharmaceuticals
.

Are investors shorting X4 Pharmaceuticals?

X4 Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 289,700 shares, an increase of 12.1% from the August 31st total of 258,400 shares. Based on an average daily volume of 101,200 shares, the days-to-cover ratio is presently 2.9 days.
View X4 Pharmaceuticals' Short Interest
.

Who are some of X4 Pharmaceuticals' key competitors?

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

Who are X4 Pharmaceuticals' key executives?

X4 Pharmaceuticals' management team includes the following people:
  • Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 50, Pay $779.45k)
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 40, Pay $541.64k)
  • Dr. Mary DiBiase, Sr. VP of Technical Operations & Quality
  • Ms. Candice Ellis, Director of Corp. Communications & Investor Relations
  • Mr. Derek M. Meisner Esq., J.D., Gen. Counsel (Age 49)
  • Ms. Ronny Mosston, Sr. VP of HR
  • Dr. Robert David Arbeit, Sr. VP of Clinical Devel. and Translational Research (Age 72)
  • Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs
  • Ms. Carrie Melvin M.B.A., Sr. VP of Devel. Operations

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $5.83.

How big of a company is X4 Pharmaceuticals?

X4 Pharmaceuticals has a market capitalization of $94.95 million. The company earns $-52,810,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis. X4 Pharmaceuticals employs 64 workers across the globe.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is www.x4pharma.com.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.